Antibiotic resistance is a growing global threat with serious health and economic consequences. Yet there is progress – from rapid PCR diagnostics and AI-driven research to new drug development and innovative funding models.
By making RT-PCR testing a routine option in outpatient and urgent care settings — and by educating all stakeholders along the clinical continuum — we can significantly reduce unnecessary antibiotic use, protect the effective drugs we still have, and ensure that bacterial infections remain treatable for future generations.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Entasis Therapeutics is being acquired by Innoviva in a deal that brings an FDA-ready antibiotic developed to address drug-resistant strains of a bacterium that infects critically ill, immunocompromised patients. Innoviva has been steadily building up its stake in Entasis, an AstraZeneca spinout, over the past two years.
By learning from the past, we may have a much better arsenal against antimicrobial-resistant bacteria in the near future.
SeLux’s believes its rapid microbe identification and antibiotic susceptibility diagnostic test will inform better clinical choices and reduce reliance on the most powerful antibiotics, thereby preserving their potency for the long-run.
The drug was developed by the non-profit TB Alliance. Some experts have said nonprofit organizations may provide a long-term solution to the growing problem of antibiotic resistance.
Alan Murray on improving access for medical transportation.
In the wake of Achaogen's bankruptcy, experts discussed ways to ensure new treatments are available to combat drug-resistant bacteria that threaten a post-antibiotic world.
With New Enterprise Associates at the helm of the round, the company is setting out to develop antibiotics for drug-resistant bacterial infections.
An estimated 23,000 deaths can be tied to antibiotic-resistance every year, according to data from the CDC's website.
Dr. Jerome Adams has been sworn in as the nation's 20th Surgeon General and these areas should be his priorities.
Solera Health is working to streamline employer contracting with health tech.
With the help of the 2012 GAIN Act, Zavante Therapeutics is breathing new life into a decades-old antibiotic.
Theories from economics could play a role in how we combat antibiotic resistance.
A team of Israeli researchers have developed a test that can distinguish whether an infection stems from a virus or a bacteria – a simple but potentially impactful screener that could cut down unnecessary use of antibiotics. Hailing from Israel-based biotech MeMed, the overarching goal is to curb antibiotic resistance – which is growing thanks […]
Transatlantic antibiotics maker Nabriva Therapeutics just raised an enormous swath of cash – it just closed a $120 million Series B round to treat serious and highly resistant bacterial infections. It’s validation for a largely underused class of antibiotics – pleuromutilins – and a step in the direction to address global antibiotic resistance. The first, $50 million tranche […]
Yesterday we discussed the pros and cons of President Obama’s plan to tackle the pressing issue of antibiotic-resistant bacteria from critics, which causes 2 million illnesses each year in the United States and 23,000 deaths. Today, the announcement was made officially, and the president has commented on the issue at hand. “There are parts of […]